News Tag: Other Corporate Information

The development of active Dosell units remained positive during June, while several larger processes are now in planning, preparation and start-up after the summer. The focus is therefore on converting the strong pipeline built up during the spring into concrete implementations and more active units during the second half of the year.

Sweden – strong pipeline ahead of Q3
In Sweden, the ADDA agreement continues to create new opportunities and clearer processes for municipalities that want to introduce medication dispensers on a larger scale. During June, we have continued dialogues with several municipalities that completed their preparatory work during the spring and are now planning for call-offs and start-ups after the summer.

We currently have six municipalities with planned start-up during August and September. In addition, dialogues are ongoing with a further twelve municipalities where contract proposals are on the table and where the ambition is to start during Q3.

At the same time, several municipalities continue to conduct their own procurements alongside ADDA, which means that we continue to work in parallel across several different processes. Our view is that the market is now maturing rapidly. More municipalities have moved from wanting to understand what a medication dispenser is, to actively planning how Dosell can be introduced into their operations.

To meet the increased level of activity, we have continued to strengthen the organisation, including through the recruitment of a new implementation specialist with experience from close care and municipal operations. This strengthens our ability to carry out start-ups with high quality and create confidence among both staff and users.

The Netherlands – pipeline, structure and upcoming deliveries
In the Netherlands, we continue to build a stronger foundation for scaling. During the spring, we have strengthened the local organisation and introduced better structure for pipeline management, customer follow-up, planned rollouts and prioritisation of business opportunities.

We see very clear potential in the Dutch market. Several care organisations are in active dialogues regarding scaling, and the work is now focused on converting these opportunities into planned rollouts, active units and recurring revenue. The market places high demands on integrations, support and adapted implementation flows, which makes structure and the right prioritisation essential in order to scale effectively.

As previously communicated, manufacturing has been affected by delayed components. These are now expected to arrive in early July, which means that manufacturing can begin during the month. The objective is to start delivering new Dosell units from August to customers in the Netherlands that are awaiting the updated version, in line with each organisation’s readiness for rollout. This is an important piece of the puzzle in enabling us to scale up in the Netherlands during the second half of the year.

Other markets
In Norway, work continues together with existing and potential partners. We continue to see growing interest in medication dispensers and are working to create the right conditions for upcoming implementations.

In Finland, Iceland and Spain, work continues together with our partners. Although we do not have any major news to communicate from these markets this month, important dialogues and preparations are ongoing, strengthening our opportunities for the coming periods.

Product, operations and organisation
During June, we have continued to work on product improvements, integrations, onboarding and operational stability. As more customers and markets are added, this work becomes increasingly important. Our ambition is for Dosell to be easy to implement, safe to use and scalable for both small and large organisations.

We are also using the summer to strengthen our internal processes. This includes training materials, clearer customer journeys, better follow-up and improved structure in sales and implementation. This may not always be the most visible work externally, but it is critical to enabling us to grow faster and in a more controlled way during the autumn.

Summer break for the monthly letter
As July is normally a quieter period for many customers and partners, the monthly letter will now take a summer break. The next monthly letter will be published in September and will cover the month of August. As usual, we will communicate separately if any events occur that need to be disclosed in accordance with applicable regulations.

Looking ahead – focus on start-ups, delivery and autumn growth
We enter the summer with a stronger pipeline than before, both in Sweden and the Netherlands. At the same time, it is important to be clear that much of this pipeline now needs to be converted into actual implementation during the second half of the year.

Our priorities going forward are to:
• Carry out planned start-ups in Sweden during August and September
• Continue work with call-offs through ADDA
• Drive ongoing contract dialogues towards decisions
• Begin deliveries from the new production to the Netherlands
• Continue strengthening the organisation and our implementation processes
• Support our partners in other markets

We continue to work long-term and with clear focus to make Dosell a natural part of the future of medication management.

Thank you for following our journey. We wish you a great summer.

The purpose of the transfer is to create private liquidity to enable Anders Segerström’s participation in the company’s long-term incentive program for employees, LTIP 2026:I, which was resolved by the Annual General Meeting on 28 May 2026. The program is designed to create long-term alignment between employees and shareholders and is linked to long-term value creation in the company.

Following the transaction, Anders Segerström’s holding amounts to 2,558,550 B shares in iZafe Group AB.

“I remain strongly committed to iZafe for the long term. The sale is carried out to enable my participation in the company’s long-term incentive program, where the value is clearly linked to long-term value creation for shareholders. It also feels positive that the shares are transferred to a person who has previously shown support for the company,” says Anders Segerström, CEO of iZafe Group AB.

The number of active Dosell units increased by approximately 4 percent compared with the previous month. This is an important confirmation that we continue to grow, while also being clear that implementations in municipal health and social care often require planning, training, anchoring and gradual scaling.

During May, we also passed 1 million completed dispensations. For us, this is one of the most important metrics, as it shows how many times Dosell has helped ensure that people receive the right medication at the right time. It is also clear evidence that Dosell is not only being installed, but is increasingly being used in daily care.

Sweden: continued activity following ADDA
In Sweden, work continues with call-offs, procurements and implementations. The ADDA agreement has increased the visibility of medication dispensers and created a clearer path for municipalities that want to implement the solution on a larger scale. At the same time, we see that some municipalities continue to choose to conduct their own procurements, which means that we are working in parallel across several different processes.

During May, we have maintained a high level of activity with customer meetings, training sessions, start-ups and tender presentations. Several municipalities are at different stages of the process, from initial demonstrations to preparations for implementation. We also see that existing customers continue to expand their use of Dosell, which is an important signal that the solution creates value in practice.

We have also continued to strengthen our organisation to meet the increased level of activity. New resources within implementation and customer-facing work are important in order to shorten lead times, maintain high quality in start-ups and ensure that more municipalities can move from pilot projects to broader implementation in a secure and structured way.

Vitalis: clear market interest
At the beginning of May, we participated for the first time with our own booth at Vitalis. The fair confirmed the growing interest in medication dispensers and resulted in a large number of relevant dialogues with municipalities, regions, partners and decision-makers. These discussions reinforced the picture of a growing need for solutions that increase safety, independence and efficiency in medication management.

The Netherlands: structure for continued growth
In the Netherlands, work continues to build a more scalable commercial structure. During the spring, we have strengthened the local organisation and are now working more systematically with pipeline, customer follow-up, implementations and integrations.

During May, dialogues with both existing and new care organisations continued. Several customers are now evaluating how Dosell can be scaled up following initial use, and we continue to see interest from organisations that want to make their medication management more efficient.

At the same time, we are building a stronger pipeline for the period after the summer, when several customers are expected to be able to take the next step in their implementations. Together with the work on integrations and simplified implementation flows, this creates better conditions for scaling the solution effectively in the Dutch market.

Norway and other markets
In Norway, work continues together with existing and new potential partners, where we see growing interest in medication dispensers. The focus is on creating the right conditions for implementation and further market development.

In Finland, Iceland and Spain, work continues together with our partners. Although we do not have any specific news to communicate from these markets this month, we continue to see long-term potential and are working to strengthen our presence, dialogues and conditions for future implementations.

Product, quality and organisation
For Dosell to become the natural choice in medication management, we need to continue developing both the product and our ways of working. For this reason, there is a strong focus on stability, user experience, onboarding, integrations and operational reliability.

At the same time, we continue to strengthen the organisation as the level of activity increases. Recruitment, onboarding and structure take time in the short term, but are necessary for us to be able to manage more parallel implementations while maintaining high quality for customers, partners and users.

Our ambition is not only to grow quickly, but to grow in a way that is sustainable and strengthens Dosell’s position in the long term.

Looking ahead: methodically moving from interest to active units
We are now moving forward with a clear focus on execution. This means converting interest into agreements, agreements into start-ups, and start-ups into active units that are used every day.

Our priorities going forward are to:
• Continue work with call-offs and procurements in Sweden
• Carry out planned implementations with high quality
• Drive scaling in the Netherlands
• Strengthen the organisation in line with growth
• Continue developing our international partner dialogues
• Continue improving the product, onboarding and operational reliability

We continue to work long-term and with clear focus to make Dosell a natural part of the future of medication management.

Thank you for following our journey.

During the month, we continued to strengthen the organization in order to meet growing demand and manage an increasing number of start-ups, installations and customer dialogues. The number of active Dosell units increased during the month by approximately 5 percent compared with the previous month, driven by new implementations and expansions among existing customers.

At the same time, we see clear signs that the market for medication dispensing devices continues to mature rapidly, particularly in Sweden, where the ADDA framework agreement is now creating new opportunities for municipalities and regions to initiate broader rollouts.

Sweden – Increased Activity Following ADDA
Since the ADDA framework agreement came into effect, we have seen a clear increase in interest from municipalities that are now evaluating how Dosell can be implemented on a larger scale. Several municipalities are planning call-offs under the framework agreement, and we are engaged in ongoing dialogues regarding upcoming implementations.

During April, we continued to carry out a large number of demonstrations, start-ups and customer meetings. We also see that several processes are moving faster than before, with some municipalities now progressing from initial dialogue to decision within a significantly shorter timeframe.

We have also demonstrated Dosell to a first major municipality through ADDA and are now awaiting feedback on the next steps in the process.

At the same time, more municipalities are continuing to move from pilot projects to broader deployment. This confirms that medication dispensing devices are increasingly being viewed as a natural part of future medication management and preventive care.

Vitalis – Strong Interest in Medication Dispensing Devices
At the beginning of May, we participated for the first time with our own booth at Vitalis, the largest e-health and welfare technology exhibition in the Nordic region. The event was highly successful, and we held a large number of meetings with municipalities, regions and collaboration partners.

A clear trend from this year’s exhibition was that medication dispensing devices are now a prioritized area for many municipalities and regions. The ADDA framework agreement has contributed to increased visibility for the topic, and several presentations and discussions during the event focused on the benefits of digital medication management and how municipalities are working to strengthen independence and safety for users.

Among other things, results were presented from municipalities already using medication dispensing devices, showing very high levels of perceived safety and independence.

The Netherlands – Continued Focus on Scaling
In the Netherlands, we continue to build for long-term growth. The organization has been strengthened with additional resources to manage more implementations and a higher pace of scaling in the coming quarters.

During April, we continued dialogues with both new and existing care organizations regarding the scaling of Dosell. A particular focus is on integrations and simplified implementation flows, which are key to scaling the solution efficiently in the Dutch market.

Finland and Other Markets
We continue our work in Finland, where we submitted a major tender in April with significant potential. At the same time, dialogues and activities continue together with our partners in Norway, Iceland and Spain.

Across several markets, we see the same overall trend as in Sweden: an increasing focus on digitalization, independence and more efficient medication management within healthcare and social care.

Product, Quality and Scalability
To meet the increasing activity level and prepare for more parallel start-ups, we have strengthened the organization within implementation, support, technology and quality assurance. The purpose is to reduce lead times, improve onboarding and ensure stable operations as Dosell is scaled across more markets.

We also continue to develop our platform and workflows with a focus on scalability, user experience and stability. Among other things, further work has been carried out on our remote care platform and new onboarding flows.

Looking Ahead – From Pipeline to Implementation
After a period focused on tenders, partnerships and market development, we are now entering a phase where implementation and scaling are becoming increasingly important. In the coming months, the work will primarily focus on converting the increased interest into concrete start-ups, more active units and scalable implementations.

Our priorities going forward are to:

• Carry out start-ups and implementations in new municipalities
• Continue the work with call-offs through ADDA
• Drive scaling in the Netherlands
• Strengthen the organization in line with growth
• Continue developing our international partner dialogues

We remain committed to working long term and purposefully to make Dosell a natural part of the future of medication management.

Thank you for following our journey.

The award relates to tender area Group B, simple medication dispensing device, where Dosell is offered as a solution for medication management within municipal healthcare and social care. Delivery and implementation are carried out in collaboration with Atea Sverige AB.

The contract entered into force on April 1, 2026 and is valid for two years, with the option to extend for an additional one plus one years. Deliveries will be carried out gradually during the contract period based on call-offs from the municipalities.

The estimated total volume in the procurement amounts to approximately 500 units, which at full deployment corresponds to an annual recurring revenue of approximately SEK 3.7 million for iZafe Group.

“We are pleased to have the opportunity, together with Atea Sweden, to deliver our solution to Västervik and the collaborating municipalities, several of which are already using it today,” says Anders Segerström, CEO of iZafe Group AB.

Dosell is a connected medication dispensing device that supports correct and safe medication management in the home. The solution is used within municipal operations and is designed to meet requirements for functionality, safety and user-friendliness.

Through this contract, iZafe Group strengthens its presence in the Swedish municipal market within digital medication management.

ISO/IEC 27001 is a globally recognized standard that ensures organizations work in a structured and systematic way to protect information, manage risks, and maintain a high level of security across their operations.

The certification confirms that iZafe has implemented a robust and scalable information security management system, in line with the requirements of customers, partners, and regulatory authorities in the markets where the company operates.

“This is an important milestone for iZafe and a clear validation of the work we have done to build a secure and scalable platform. The certification strengthens our competitiveness in tenders, simplifies dialogues with larger customers and partners, and creates strong conditions for continued international expansion,” says Anders Segerström, CEO of iZafe Group.

As demand for digital healthcare solutions continues to grow, so do the requirements for secure handling of data and systems. With the ISO/IEC 27001 certification, iZafe Group further strengthens its position as a trusted provider in digital medication management and remote care, taking another step forward in its commercial development.

More information about iZafe Group’s work within information security and compliance can be found on the company’s Trust Center: https://compliance.izafegroup.com/

The certification is valid until April 2029 and will be subject to annual audits.

Sweden – ADDA in effect and growing demand
On March 31, the ADDA framework agreement came into effect, enabling municipalities and regions to procure Dosell directly through the national framework. We already have our first contract in place and are in dialogue with several municipalities planning to place orders in the near term.

During March, we received orders from two larger municipalities that have decided to switch from previous solutions to Dosell, corresponding to approximately 150 and 100 units respectively. Deployment will take place gradually throughout Q2.

We have also been awarded a contract in the Jönköping region through a procurement outside of ADDA, opening up new use cases related to more preventive care.

During the month, we conducted 16 demonstrations and initiated implementations in three new municipalities. We continue to see a clear trend where more municipalities move from pilot projects to broader deployment.

Organization – investing to enable scale
Following the directed share issue of approximately SEK 19.8 million, we are actively strengthening the organization across sales, implementation, and support.

This work is crucial for our continued growth, but it also means that a significant amount of time and focus is currently devoted to recruitment, onboarding, and building internal structures. This impacts short-term capacity but is a necessary investment to meet demand and scale the business effectively over time.

Netherlands – investments ahead of scaling
In the Netherlands, we continue to strengthen the foundation for growth. The organization has been reinforced with both a Country Manager and an Account Manager, while we have also invested in a larger warehouse to ensure short delivery times.

We have experienced some production delays related to component supply, as a result of the current global situation with disrupted supply chains and longer lead times for electronic components. This means that the next larger production batch is delayed by approximately 2 to 3 months.

The upcoming production includes important adaptations that will allow us to better meet the specific requirements of the Dutch market. This strengthens our position and enables a broader rollout to more customers going forward.

The current version of Dosell is working well and is already in active use among our customers, both in the Netherlands and in other markets, with strong results. At the same time, some customers in the Netherlands have chosen to wait for the updated version before scaling up, as it is optimized for local conditions. This affects the pace in the short term, while we maintain strong delivery capacity in other markets.

Overall, this creates solid conditions for a clear acceleration in the Netherlands during Q2 and Q3.

Norway – ready for rollout
In Norway, everything is now prepared for the launch in the six municipalities included in the procurement we previously won together with our partner Vakt og Alarm. The focus is now on training and implementation.

Demand for medication dispensing solutions is high, and we have also submitted a bid in an additional procurement during the month.

Increased international interest and visibility
During March, we presented Dosell to an international delegation within elderly care from Belgium, with more than 40 participants. The level of interest was very high and confirms the strong need for the solution beyond our current markets.

We have also secured our own booth at Vitalis in May, the largest eHealth event in the Nordics, where we will meet both existing and new customers. In connection with this, our CEO Anders Segerström will also participate as a speaker and panelist on the future of medication management.

Other
During March, we were granted a European patent within data-driven medication management, strengthening our long-term position and intellectual property value.

At the same time, we continue our work together with partners in Finland, Iceland, and Spain.

Looking ahead – focus on delivery and execution

We are now entering Q2 with a strong pipeline, more contracts in place, and an organization that is being strengthened.

Our focus going forward is to:

• Scale up deliveries linked to ADDA and existing agreements
• Execute new municipal implementations
• Continue strengthening the organization
• Drive expansion in the Netherlands
• Support rollouts in Norway

We are in a phase where much of the work is focused on enabling the next stage of growth, with the effects expected to become more visible during Q2 and onwards.

We continue to work with determination to make Dosell a natural part of the future of medication management.

Thank you for following our journey.

Dosell has been awarded sub-contract B, relating to a basic medication dispensing device, where the company’s solution has been evaluated as meeting high standards in terms of functionality, user-friendliness and quality.

The agreement is a framework agreement enabling successive call-offs from both the region and municipalities. The agreement entered into force on April 1, 2026, and runs for an initial period of two years, with the possibility of extension up to a total of four years. As a framework agreement, no volumes are guaranteed, and demand is realized through ongoing call-offs during the contract period.

“This is a strategically important award for us. The fact that an entire region together with its municipalities chooses to procure within a common structure creates strong conditions for broad and gradual implementation over time. It confirms that Dosell meets the requirements of modern healthcare and strengthens our position as a leading player in the field,” says Anders Segerström, CEO of iZafe Group.

The total estimated value of the procurement amounts to approximately SEK 55 million, with a maximum ceiling value of SEK 82.5 million. No allocation of value between the different sub-contract areas has been specified.

The award strengthens iZafe Group’s presence in the Swedish market and establishes an important platform for continued growth and rollout of Dosell within public healthcare and social care.

The patent covers a system where patient data from sensors is analyzed to identify changes in health status. Based on this information, medication treatment can be adjusted over time, enabling more personalized and proactive care.

Although the patent is not directly linked to Dosell’s current functionality, it aligns with iZafe Group’s strategic direction of combining medical technology, data, and future AI-based analytics.

Through this patent, the company strengthens:

• its technological platform for future solutions
• its intellectual property value
• its position within a growing global healthcare segment

In the long term, the technology enables solutions where treatment can be optimized based on real patient data, contributing to improved patient safety and more efficient healthcare.

“This patent is an important step in our long-term strategy. It clearly demonstrates the direction we are moving in—towards more data-driven, intelligent, and personalized healthcare. At the same time, it strengthens our intellectual property and future potential,” says Anders Segerström, CEO of iZafe Group.